2022
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. European Journal Of Heart Failure 2022, 24: 603-619. PMID: 35239201, DOI: 10.1002/ejhf.2471.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCardiologyChronic DiseaseConsensusHeart FailureHumansKidneySodium-Glucose Transporter 2 InhibitorsStroke VolumeVentricular Dysfunction, LeftConceptsChronic heart failureHeart failureRenal functionEjection fractionClinical practiceConsensus documentSodium-glucose cotransporter 2 inhibitorsGuideline-directed medical therapyReduced ejection fraction patientsEjection fraction patientsHeart Failure AssociationCotransporter 2 inhibitorsEuropean SocietyPharmacologic treatment optionsPoor renal functionDisease-modifying therapiesGood clinical practiceTreatment-induced changesDrug implementationHF drugsCardiology guidelinesESC guidelinesRenal effectsMedical therapyLifesaving therapy
2019
Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy
Latif SR, Nguyen VQ, Peters DC, Soufer A, Henry ML, Grunseich K, Testani J, Hur DJ, Huber S, Mojibian H, Dicks D, Sinusas AJ, Meadows JL, Papoutsidakis N, Jacoby D, Baldassarre LA. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy. The International Journal Of Cardiovascular Imaging 2019, 35: 1309-1318. PMID: 30790116, DOI: 10.1007/s10554-019-01551-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAtrial Function, LeftAtrial RemodelingCardiomyopathy, HypertrophicContrast MediaFemaleFibrosisHeart AtriaHeart VentriclesHumansHypertrophy, Left VentricularMagnetic Resonance Imaging, CineMaleMiddle AgedOrganometallic CompoundsPredictive Value of TestsRetrospective StudiesVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLA fibrosisLV-LGEHypertrophic cardiomyopathyLA-LGELV fibrosisLV parametersLV end-diastolic volumeSetting of HCMAldosterone system inhibitionLate gadolinium enhancement (LGE) sequencesLV global strainLeft ventricular massEnd-diastolic volumeLeft atrial fibrosisMaximum wall thicknessFibrosis correlatesRenin-AngiotensinVentricular strainMedication usageAtrial fibrosisLV remodelingVentricular massLV massSystem inhibitionDiastolic volume